Transcranial Magnetic Stimulation (TMS) Effects Using Magnetoencephalography (MEG) Study

Official title

An Investigation of TMS Effects Using Magnetoencephalography (MEG) Among Individuals With and Without Heavy Alcohol Use

Overview

Alcohol use disorder (AUD) is a complex chronic brain disease characterized by compulsive alcohol use, loss of control over drinking, and negative emotional states. Extensive research has identified the general neural circuitry underlying AUD. There is an exciting opportunity to intervene in AUD using neuromodulation. Transcranial magnetic stimulation (TMS) offers a non-invasive method to modulate brain activity, making it a promising tool for investigating, modulating, and potentially treating AUD. However, the precise effects of TMS on neural circuits involved in AUD and the mechanisms underlying these effects must first be understood. Magnetoencephalography (MEG) is a neuroimaging method that provides direct measurement of brain activity within neural circuits with high temporal resolution. Critically, MEG can measure brain activity in a wide range of frequencies that are consistent with those targeted by TMS. The goal of this proposal is therefore to collect preliminary and feasibility data to support a future NIH grant application that would use MEG to investigate TMS effects in individuals with AUD (iAUD).

Detailed description

This proposal uses a mixed, between-group, within-subject design. The study will investigate the acute effects of different TMS pulse sequences in participants without AUD (non-AUD), and compare active/sham iTBS across non-AUD and AUD. On each study day, participants will complete a pre-TMS baseline MEG scan (10 min resting state), followed by a TMS pulse sequence, then complete 3 more MEG scans (immediately post-TMS, 1 hour post-TMS, and 2 hours post-TMS). Each TMS pulse sequence will be administered on a separate day and will be matched by the number of pulses administered (1200 pulses) and the total duration of administration time (20 min). The sham condition will control for auditory and sensory side effects associated with TMS. TMS will be applied to the left DLPFC, identified by the EEG F3 coordinate. Participants will either complete 4 study visits (n = 5) and receive 1 Hz, 10 Hz, iTBS, and sham, each on a separate day; or participants will complete 2 study visits (n = 5) and receive iTBS and sham, each on a separate day. Participants will also receive a structural MRI scan in order to map the MEG outcome data onto their own anatomical brain image.

Interventions

• Device Sham iTBS
  Participants will receive sham iTBS
• Device Active iTBS
  Participants will receive active iTBS
• Device 10 Hz TMS
  Participant will receive 10 Hz TMS
• Device 1 Hz TMS
  Participant will receive 1 Hz TMS

Primary outcome measures

• Number of Adverse Events Potentially Related to TMS [Time frame: Through study completion 1 year]

Eligibility criteria

Inclusion Criteria non-AUD Participants:

• Diagnostic and Statistical Manual of Mental Disorders (DSM-5) score for AUD = 0
• Alcohol Use Disorders Identification Test (AUDIT) score ≤ 7
• Is not a heavy alcohol consumer

Inclusion Criteria AUD Participants:

• DSM-5 score for AUD ≥ 3
• AUDIT score ≥ 8
• Is a heavy alcohol consumer

Exclusion criteria

• Current substance use disorder other than alcohol use disorder and/or frequent use of non-prescribed psychoactive substances.
• Current serious psychiatric disorder, and/or any history of a psychotic disorder
• Any health problem that would interfere with the study or could be aggravated by study procedures (e.g., history of migraines, claustrophobia).
• Is currently taking or initiates a medication known to affect alcohol intake and/or craving.
• History of traumatic brain injury resulting in hospitalization, loss of consciousness, and/or having ever been informed he/she has an epidural, subdural, or subarachnoid hemorrhage.
• Does not meet safety criteria for TMS or MRI.
• Females of childbearing potential who are pregnant (by urine HCG), planning to become pregnant, nursing, or who are not using a reliable form of birth control.
• Is at an elevated risk of seizure (i.e. has a history of seizures, is currently prescribed medications known to lower seizure threshold and has had a change in their medication).
• Clinical Intake Withdrawal Assessment (CIWA>5) (to prevent delivering TMS to individuals in withdrawal).
• Not able to read and understand questionnaires, assessments, and/or the informed consent.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Allocation

Randomized

Model

Crossover

Masking

Double blind

Primary purpose

Basic science

Study locations

United States · 1 center

• Wake Forest University Health Sciences — Winston-Salem

Identifiers

NCT: NCT06770556 · IRB00123420

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗